EUVIMEDEUVIMED entdecken
Crossref

Longitudinal evolution of O -(2-[18F]-fluoroethyl)-L-tyrosine PET metrics in serial imaging during glioblastoma progression

Norbert Galldiks iD, Keith George Ciantar iD, Isabelle Stetter iD, Julia Hilgers iD, Jana-Marie Peplinski iD, Manuel Kraft iD, Jurij Rosen iD, Chistian Filss, Gabriele Stoffels iD, Karl-Josef Langen, Gereon R Fink, Jan-Michael Werner iD und 1 weitere

Neuro-Oncology · 13.11.2026

DOI: 10.1093/neuonc/noag265 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology, online erschienen am 13.11.2026. Verfasst von Norbert Galldiks und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Faculty of Medicine and University Hospital Cologne, Cologne, Germany. Die Arbeit nennt 37 Literaturangaben. Gefördert von: German Research Foundation (DFG).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Most studies evaluating O-(2-[18F]-fluoroethyl)-L-tyrosine (FET) PET for glioblastoma progression rely on single-scan assessments, leaving diagnostic uncertainties in cases with borderline tracer uptake. We evaluated metabolic activity evolution during the transition of glioblastoma progression using serial FET PET to determine whether longitudinal parameter changes improve diagnostic certainty. Patients and Methods Between 2016 and 2026, 182 patients with glioblastoma undergoing 690 dynamic FET PET scans (median, 3; range, 2-12) were retrospectively evaluated. Eligible cases required documented progressive disease according to RANO 2.0 criteria and serial FET PET at least 2 time points (at suspected progression and within a 6-month prior window). Static PET parameters, ie tumor-to-brain ratios (TBRmean, TBRmax) and metabolic tumor volume (MTV), and their longitudinal changes were evaluated according to PET RANO 1.0 criteria, alongside additional dynamic PET parameters (time-to-peak). Single-scan metrics and serial changes were compared in cases with borderline uptake.

Results

Ninety patients with 102 confirmed progression events met all selection criteria (median interscan interval, 2.7 months). At progression, TBRmean, TBRmax, and MTV increased significantly (P < .001). Median percentage increases were modest for TBRmean (+4%) and TBRmax (+17%), whereas MTV exhibited a substantial expansion (+182%). In cases with borderline uptake, applying a longitudinal MTV increase criterion of ≥40% per PET RANO 1.0 substantially improved progression detection to up to 89%, yielding a 14% higher diagnostic detection rate compared to single-scan thresholds.

Conclusions

In glioblastomas with documented RANO 2.0 progression, integrating longitudinal MTV changes markedly improves diagnostic certainty over single-scan uptake metrics, particularly in challenging cases with borderline uptake.

Schlagwörter

Stichwörter der Autor:innen

amino acid PETgliomavolumetry

Autor:innen und Institutionen

  • Department of Neurology, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
  • Institute of Neuroscience and Medicine (INM-3, INM-4), Research Center Juelich, Juelich, Germany.
  • Center of Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), Germany.
  • Institute for Imaging and Computer Vision, RWTH Aachen University, Aachen, Germany.
  • Department of Psychiatry, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.
  • Department of Nuclear Medicine, University Hospital RWTH, Aachen, Germany.

ORCID-Profile: Norbert Galldiks, Keith George Ciantar, Isabelle Stetter, Julia Hilgers, Jana-Marie Peplinski, Manuel Kraft, Jurij Rosen, Gabriele Stoffels, Jan-Michael Werner, Philipp Lohmann

Förderung

  • German Research Foundation (DFG)

Zitieren

APA

Galldiks, N., Ciantar, K. G., Stetter, I., Hilgers, J., Peplinski, J. M., Kraft, M., Rosen, J., Filss, C., Stoffels, G., Langen, K. J., Fink, G. R., Werner, J. M., & Lohmann, P. (2026). Longitudinal evolution of O -(2-[18F]-fluoroethyl)-L-tyrosine PET metrics in serial imaging during glioblastoma progression. Neuro-Oncology. https://doi.org/10.1093/neuonc/noag265

Vancouver

Galldiks N, Ciantar KG, Stetter I, Hilgers J, Peplinski JM, Kraft M, et al. Longitudinal evolution of O -(2-[18F]-fluoroethyl)-L-tyrosine PET metrics in serial imaging during glioblastoma progression. Neuro-Oncology. 2026. doi:10.1093/neuonc/noag265

BibTeX
@article{Galldiks2026,
  author = {Galldiks, Norbert and Ciantar, Keith George and Stetter, Isabelle and Hilgers, Julia and Peplinski, Jana-Marie and Kraft, Manuel and Rosen, Jurij and Filss, Chistian and Stoffels, Gabriele and Langen, Karl-Josef and Fink, Gereon R and Werner, Jan-Michael and Lohmann, Philipp},
  title = {Longitudinal evolution of O -(2-[18F]-fluoroethyl)-L-tyrosine PET metrics in serial imaging during glioblastoma progression},
  journal = {Neuro-Oncology},
  year = {2026},
  doi = {10.1093/neuonc/noag265}
}
Kostenlos starten →